Serotonin noradrenaline reuptake inhibitors

2012 ◽  
pp. 48-56 ◽  
Author(s):  
Michel Bourin
Keyword(s):  
Noradrenaline Reuptake

(R)-Sila-venlafaxine: A selective noradrenaline reuptake inhibitor for the treatment of emesis

2006 ◽  
Vol 16 (9) ◽  
pp. 2555-2558 ◽  
Author(s):  
Graham A. Showell ◽  
Matthew J. Barnes ◽  
Jürgen O. Daiss ◽  
John S. Mills ◽  
John G. Montana ◽  
...  
Keyword(s):  
Reuptake Inhibitor ◽  
Noradrenaline Reuptake ◽  
Noradrenaline Reuptake Inhibitor

Efficacy and adverse events of selective serotonin noradrenaline reuptake inhibitors in the management of postoperative pain: A systematic review and meta-analysis

2021 ◽  
Vol 75 ◽  
pp. 110451
Author(s):  
Alexander Schnabel ◽  
Stephanie Weibel ◽  
Sylvia U. Reichl ◽  
Michael Meißner ◽  
Peter Kranke ◽  
...  
Keyword(s):  
Systematic Review ◽  
Postoperative Pain ◽  
Adverse Events ◽  
Meta Analysis ◽  
Selective Serotonin ◽  
Noradrenaline Reuptake

scholarly journals Antihyperalgesic Activity of Atomoxetine on Diabetes-Induced Neuropathic Pain: Contribution of Noradrenergic and Dopaminergic Systems

Molecules ◽  
2018 ◽  
Vol 23 (8) ◽  
pp. 2072 ◽  
Author(s):  
Mustafa Barbaros ◽  
Özgür Can ◽  
Umut Üçel ◽  
Nazlı Turan Yücel ◽  
Ümide Demir Özkay
Keyword(s):  
Neuropathic Pain ◽  
Therapeutic Potential ◽  
Sch 23390 ◽  
Withdrawal Threshold ◽  
Dopaminergic Systems ◽  
Noradrenaline Reuptake ◽  
The Central Nervous System ◽  
Streptozotocin Induced Diabetes ◽  
Noxious Stimuli ◽  
Inhibitor Drug

Atomoxetine is a selective noradrenaline reuptake inhibitor drug. Based on the knowledge that agents increasing monoamine levels in the central nervous system have therapeutic potential for neuropathic pain, it is planned to investigate the possible efficacy of atomoxetine on diabetes-induced hyperalgesia, in this study. Randall-Selitto (mechanical noxious stimuli) and Hargreaves (thermal noxious stimuli) tests were used to evaluate nociceptive perception of rats. Obtained data indicated that streptozotocin-induced diabetes causes significant decreases in the paw withdrawal threshold and paw withdrawal latency values of the animals, respectively. However, atomoxetine administered at 3 mg/kg/day for 7 and 14 days improved these diabetes-induced hyperalgesia responses. Furthermore, antihyperalgesic activity was antagonized with α-methyl-para-tyrosine methyl ester, phentolamine, propranolol, and sulpiride pre-treatments. The same effect was not reversed, however, by SCH 23390. These findings demonstrated, for the first time, that atomoxetine possesses significant antihyperalgesic activity on diabetes-induced neuropathic pain and this effect seems to be mediated by α- and β-adrenergic and D2/D3 dopaminergic receptors. Results of this present study seem to offer a new indication for an old drug; atomoxetine, but these preclinical data should first be confirmed with further well-designed clinical trials.

scholarly journals Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration

2008 ◽  
Vol 12 (05) ◽  
pp. 687 ◽  
Author(s):  
Joan B. O'Sullivan ◽  
Karen M. Ryan ◽  
Niamh M. Curtin ◽  
Andrew Harkin ◽  
Thomas J. Connor
Keyword(s):  
Rat Cortex ◽  
Noradrenaline Reuptake
Sign in / Sign up

Export Citation Format

Share Document